| Code | CSB-RA017647MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ongericimab, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted enzyme that plays a critical role in cholesterol homeostasis by binding to low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, promoting their lysosomal degradation. By reducing LDLR availability, elevated PCSK9 levels lead to increased circulating LDL cholesterol, a major risk factor for atherosclerotic cardiovascular disease, familial hypercholesterolemia, and coronary artery disease.
Ongericimab is a therapeutic monoclonal antibody designed to inhibit PCSK9, thereby preventing LDLR degradation and enhancing LDL cholesterol clearance from the bloodstream. This biosimilar antibody provides researchers with a valuable tool for investigating PCSK9 biology, lipid metabolism pathways, and cardiovascular disease mechanisms. It supports studies examining cholesterol regulation, receptor trafficking, and the development of lipid-lowering therapeutic strategies in preclinical models and biochemical assays.
There are currently no reviews for this product.